Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

NCT ID: NCT05867914

Last Updated: 2024-02-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-04
• Study Completion Date: 2024-03-29

Brief Summary

A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD

Detailed Description

This is a multi-center early feasibility study evaluating the safety and tolerability of the 3P-100 device which creates and delivers iNO (2 mg/hr and 6 mg/hr) for the treatment of subjects with PH-ILD. All subjects will use the 3P-100 device and receive iNO (2 mg/hr and 6 mg/hr) via the 3P-100 device, aiming for ~4-4.5 hours of treatment across both device settings.

Conditions

Hypertension, Pulmonary; Lung Diseases, Interstitial

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Inhaled Nitric Oxide (iNO)

eNOfit an Electric Nitric Oxide (NO) Ambulatory Production and Delivery System, Delivering Nitric Oxide for Inhalation

The treatment period with inhaled Nitric Oxide (iNO) will include start of iNO at a device setting of 2 mg/hr iNO for 2 hours (+15 minutes), device setting escalation to 6 mg/hr iNO for 2 hours (+15 minutes) and then weaning of iNO treatment

Group Type: EXPERIMENTAL

Inhaled Nitric Oxide (iNO)

Intervention Type: DEVICE

eNOfit system delivering iNO

Interventions

Inhaled Nitric Oxide (iNO)

eNOfit system delivering iNO

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male or female age 22 to < 85 years old

2. Provides signed informed consent for study participation

3. Diagnosis of any form of advanced Interstitial Lung Disease or Combined Pulmonary Fibrosis and Emphysema (CPFE) at any time, based on clinical, pulmonary function, serological, and Computed Tomography (CT) radiologic evidence (which demonstrates evidence of moderate to severe diffuse parenchymal lung disease)

4. A prior Right Heart Catheterization (RHC) at any time before SV that demonstrates PH with a Pulmonary Vascular Resistance (PVR) >2.0 Wood Units (WU), a mean Pulmonary Arterial Pressure (mPAP) > 20 mmHg, and a Pulmonary Capillary Wedge Pressure (PCWP) ≤ 15 mmHg. A PCWP >15 mmHg is not exclusionary if a left ventricular end diastolic pressure (LVEDP) is available and is ≤ 15 mmHg by left heart catheterization AND/OR Previous Echocardiography with an intermediate/high probability of PH (European Society of Cardiology definition)

5. New York Heart Association (NYHA) functional class II-IV

6. Self-reported use of long-term O2 therapy (LTOT) less than or equal to 10 L/minute at rest and while exercising, defined as use for at least 12 hours per day for at least 30 days prior to SV

7. Is willing to comply with treatment with iNO and procedures including using the 3P-100 device and wearing a nasal cannula for at least 4 hours at V1

8. Is able to wear a 3P-100 device while sitting and ambulating intermittently in the clinic area for at least 30 minutes during SV

9. Women of child-bearing potential must agree to use the methods of birth control indicated in Appendix 1 from consent through the Telephone Call at V1 +1 Day

Exclusion Criteria

1. History or diagnosis by Investigator evaluation during SV of World Health Organization (WHO) Group I, II, IV, or V PH

2. NYHA class IV patients who are medically unfit to participate i.e., are constantly breathless at rest or have frequent symptoms of chest pain or syncope at rest or with activity

3. History or diagnosis of acute or chronic left heart failure at any time as evidenced by one or more of the following:

1. PCWP > 15 mmHg on a previous RHC (unless LVEDP is ≤15 mmHg) AND/OR LVEDP >15 mmHg by left heart catheterization

2. Previous echocardiographic findings of left ventricular systolic dysfunction with ejection fraction < 40%

3. Cardiogenic pulmonary edema

4. History of left heart failure (Prior or current use of medications given solely for the treatment of systemic hypertension are allowed)

4. History of hereditary methemoglobinemia

5. History of the following cardiovascular conditions:

1. Stenting or Coronary Artery Bypass Graft (CABG) within 60 days prior to SV

2. Myocardial infarction within the 60 days prior to SV

3. Unstable angina pectoris in the 60 days prior to SV

4. Intermittent atrial fibrillation, supraventricular tachycardia, and serious ventricular arrhythmias (e.g., ventricular tachycardia) within 60 days prior to SV. Ablated atrial flutter or Wolf-Parkinson-White (WPW) bypass tract conduction are not exclusionary

5. Cerebrovascular accident within the 60 days prior to SV

6. Has within 30 days prior to SV or during the Screening period

1. Participated in any clinical study involving an investigational drug, investigational biologic, or investigational device

2. Required unplanned hospitalization for any reason

3. Had an exacerbation of ILD requiring administration of oral or parenteral antibiotic

7. Has within the 30 days prior to SV or during the Screening period required initiation or changes in the regimen (including agents, dose, and frequency) of medications prescribed for the treatment of ILD, including but not limited to immunosuppressive / immunomodulatory medications, systemic oral or parenteral corticosteroids, and monoclonal antibodies

8. Has within 30 days prior to SV, or any time during Screening period taken one or more of the following medications or supplements chronically:

1. Oral, inhaled, or parenteral medications for the treatment of Pulmonary Arterial Hypertension (PAH) irrespective of the route of administration including, but not limited to,

• high dose calcium channel blockers
• riociguat
• prostacyclins
• prostacyclin analogues
• prostacyclin receptor agonists (e.g., selexipag)
• phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil) if the subject is on inhaled treprostinil
• endothelin receptor antagonists

2. Inhaled treprostinil (approved for PH-ILD), if the subject is on a PDE5 inhibitor for PH-ILD

Note: Inhaled treprostinil is not exclusionary as a monotherapy, however, the concurrent use of both a PDE5 inhibitor (e.g., sildenafil) and inhaled treprostinil is exclusionary. The use of either a PDE5 inhibitor or inhaled treprostinil will be allowed if both conditions are met:

• The PDE5 inhibitor or inhaled treprostinil was started more than 30 days prior to the SV.
• There have been no changes in the PDE5 inhibitor or inhaled treprostinil dosage within 30 days prior to the SV.

3. Nitrates, regardless of route of administration

4. Supplements containing L-arginine

5. Agents or medications capable of inducing methemoglobinemia where any of the SV/V1 metHb average measurements via co-oximeter are > 3.5%

Subjects should not be weaned from these therapies for the purpose of enrollment.

9. Is breastfeeding or lactating at the time of SV or intends to breastfeed at any time during their participation in the study

10. Has one of the following in their medical record or through testing performed:

1. Positive urine pregnancy test at SV or on V1 (results of the test are to be known prior to initiation of the iNO)

2. Hemoglobin < 10 g/dL (100 g/L) within 30 days of SV

3. HbA1c > 10% within 30 days of SV

4. Glomerular Filtration Rate (GFR) < 30 mL/min/1.73 m2 , calculated using the Creatinine Clearance (CKD-EPI) calculation method within 30 days of SV

5. Methemoglobin > 3.5% at SV or V1 via co-oximeter measurements

6. Thrombocytopenia with a platelet count < 50 x 103 /µL (< 50 X 109/L) within 30 days of SV

11. Has any condition at SV/V1 that could constitute a safety concern during participation in the study or could interfere with the subject's ability to comply with adherence to iNO, including but not limited to:

1. Uncontrolled systemic hypertension defined by systolic Blood Pressure (BP) > 180 mmHg and/or a diastolic BP > 110 mmHg measured manually after 20 minutes at rest on prescribed resting O2

2. History of alcohol or substance abuse within the past 365 days prior to SV. Drugs documented as prescribed by a physician or use of edible marijuana if legal in the state of residence may be allowed with approval of the Medical Monitor. Smoking and vaping of any substance is prohibited (e.g., nicotine or marijuana)

3. History of poor compliance with prior clinical studies

4. Acute or chronic physical impairment (other than dyspnea due to ILD) (e.g., neurologic, musculoskeletal, or orthopedic disorder, or dependence on mobility aids such as a cane or walker) that would limit the ability to carry and operate the 3P-100 device together with their O2 system

5. Severe right heart failure confirmed by the investigator as evidenced by two or more of the following: elevated jugular venous pressure, peripheral edema, hepatic congestion and/or ascites

6. Other known coagulopathies

12. Is a relative of Third Pole, the Contract Research Organization (CRO) or other vendor, or investigational site/institutional personnel

13. Has during the SV one or more of the following results:

1. Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) ratio < 0.7 except for CPFE

2. FVC < 40% predicted

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 84 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Third Pole Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philip Silkoff, MD

Role: STUDY_DIRECTOR

Chief Medical Officer

Locations

TGH/USF Center for Advanced Lung Disease and Lung Transplant

Tampa, Florida, United States

University of Cincinnati

Cincinnati, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Countries

United States

Other Identifiers

3P-100-ILD-00

Identifier Type: -

Identifier Source: org_study_id